Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System for T1D at ENDO 2021

 Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System for T1D at ENDO 2021

Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System for T1D at ENDO 2021

Shots:

  • Insulet reported the results from the first pivotal trial of Omnipod 5 System in patients with T1D. The trial enrolls two groups that include 28 adults & adolescents aged 14-70yrs. and 112 children aged 6-13.9yrs.
  • Results: In adults & adolescents and children, increase in time in range (70-180mg/dL) from 65% to 74% (additional 2.2hr/day) and 53% to 68% (additional 3.7hrs/day) with reduction of HbA1c from (7.16% to 6.78% and 7.67% to 6.99%), decrease in mean glucose (161 to 154 mg/dL and 183 to 160 mg/dL) respectively
  • The Omnipod 5 System received FDA’s BTD and is currently under review. Insulet is expected to launch Omnipod 5 in limited release in H1’21

Click here ­to­ read full press release/ article | Ref: Insulet | Image: National Investor Network

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post